Radiopaque Iodosilane-Coated Lipid Hybrid Nanoparticle Contrast Agent for Dual-Modality Ultrasound and X-ray Bioimaging.
Radiopaque Iodosilane-Coated Lipid Hybrid Nanoparticle Contrast Agent for Dual-Modality Ultrasound and X-ray Bioimaging.
复制标题
DOI：
10.1021/acsami.2c09104
复制
发表时间：
2022-11
影响因子：
9.5
通讯作者：
M. Attia;R. Akasov;Nancy M. Elbaz;T. Owens;Evan C Curtis;Soham Panda;R. Santos-Oliveira;F. Alexis;Forrest M. Kievit;Daniel. C. Whitehead
中科院分区：
文献类型：
--
作者：
M. Attia;R. Akasov;Nancy M. Elbaz;T. Owens;Evan C Curtis;Soham Panda;R. Santos-Oliveira;F. Alexis;Forrest M. Kievit;Daniel. C. Whitehead
在这里，我们报告了用于超声和X射线应用的用于造影剂的坚固的碘化二氧化硅-脂类纳米乳液(HSLNEs)的合成。我们通过低能量自发纳米乳化过程设计了碘化二氧化硅纳米颗粒(SNPs)、脂质纳米乳液和一系列HSLNE。二氧化硅壳层的形成需要超声作用，以在纳米乳液液滴的油/水界面上水解和聚合/凝聚碘甲基三甲氧基硅烷。所制备的纳米乳液(NE)在透射电子显微镜下呈现出均匀的球形形态。在无十六烷基三甲基溴化铵(CTAB)和存在十六烷基三甲基溴化铵(CTAB)存在下，纳米粒子的直径在20~120 nm之间，表面带正负电荷。与CTAB包衣纳米制剂不同，不含CTAB的纳米制剂在体外对小鼠巨噬细胞和人U87-MG细胞具有良好的生物相容性。评估最大耐受量评估以验证它们在体内的安全性。体外X射线和超声成像以及体内计算机断层扫描被用来监测碘标记的SNPs和HSLNEs，验证了它们显著的对比度增强特性，并暗示了它们作为未来双模式临床制剂的潜力。
Here, we report the synthesis of robust hybrid iodinated silica-lipid nanoemulsions (HSLNEs) for use as a contrast agent for ultrasound and X-ray applications. We engineered iodinated silica nanoparticles (SNPs), lipid nanoemulsions, and a series of HSLNEs by a low-energy spontaneous nanoemulsification process. The formation of a silica shell requires sonication to hydrolyze and polymerize/condensate the iodomethyltrimethoxysilane at the oil/water interface of the nanoemulsion droplets. The resulting nanoemulsions (NEs) exhibited a homogeneous spherical morphology under transmission electron microscopy. The particles had diameters ranging from 20 to 120 nm with both negative and positive surface charges in the absence and presence of cetyltrimethylammonium bromide (CTAB), respectively. Unlike CTAB-coated nanoformulations, the CTAB-free NEs showed excellent biocompatibility in murine RAW macrophages and human U87-MG cell lines in vitro. The maximum tolerated dose assessment was evaluated to verify their safety profiles in vivo. In vitro X-ray and ultrasound imaging and in vivo computed tomography were used to monitor both iodinated SNPs and HSLNEs, validating their significant contrast-enhancing properties and suggesting their potential as dual-modality clinical agents in the future.